Thu, Oct 31, 2024
USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic
More >
'Diwali Offer' Stocks by Anil Singhvi: Stock markets have been very volatile in last one month. Benchmark equity indices Sensex and Nifty fell in early trade even Thursday i.e. October 31, 2024. Amid this, investors are looking for stocks that can offer good return in long term.
Tue, Oct 29, 2024
Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year
Mon, Apr 19, 2021
Vishal Wagh, Research Head at Bonanza Portfolio says that Nifty pharma has shown consistent outperformance to the major indices and the current pandemic environment is creating a large demand for the sector. He said that as per ranking based on its performance against the NIFTY and Nifty Pharma, Cadila, Glenmark, Cipla, Sun pharma, Divislab, Auropharma, Lupin and Dr Reddy will outperform in the sector whereas, Biocon, Alkem, APL and Granules may underperform
Sat, Apr 17, 2021
The Pharma Sector has been in focus and many analysts are recommending buying into this sector on the back of Covid issues resurfacing in India. Increase in the production of Vaccines will benefit many Pharma companies including Cipla.
Mon, Apr 12, 2021
Even as wider markets were down in a significant manner, Cipla share price today rose to Rs 915, up Rs 32 or 3.6%. Cipla share price has moved from Rs 837 to Rs 915 over the last week. Cipla share price topped the Nifty Gainers list on Friday as well. The stock is seeing good buying as revenues of the company is going to increase going forward on increasing Covid worries
Fri, Apr 09, 2021
Cipla share price closed at Rs 883, up Rs 41 or 4.9%. Cipla moved from Rs 817 to Rs 883 in this week. Kotak Institutional Equities said that Lannett’s announcement of ANDA filing for Advair, a key pipeline product for Cipla, is in line with expectations and they see limited impact on Cipla’s Advair opportunity
Tue, Feb 02, 2021
Cipla delivered yet another solid quarter, driven by healthy growth across businesses (India, CGA, Europe, API). EBITDA margin came ahead of expectation at 24% (+647bps YoY, +46bps QoQ), aided by tight control on costs. Cipla is tracking ahead of its initial cost saving guidance of Rs 4-5 bn for FY21 and expects to retain part of these benefits in the coming quarters. Its US business outlook remains strong as respiratory/ niche filings add longer-term growth visibility.
Thu, Jan 14, 2021
HDFC Securities see several growth catalysts across key markets and product categories (inhalers, biosimilars, complex injectables) playing out over the next 2-3 years for Indian pharma companies. The investments made over the last few years leave them well placed to capitalise on these opportunities. With cost bases pruned and operating leverage benefits, the sector is poised to grow at 21% earnings CAGR and witness ROCE improvement of 430bps to 15% over FY20- 23e.
Tue, Jan 12, 2021
2020 was the best in recent years with the Pharma index outperforming Nifty by 45%. Jefferies remains positive on India Pharma driven by an average 13% EPS CAGR over FY21-23E. Exporters are set to gain on a stable pricing environment and complex product launches. Jefferies' key concern is the increasing role of price in driving growth in the India market and the emerging threat of e-pharmacies. Jefferies top large-cap picks are Dr. Reddy's and Cipla.
Wed, Dec 16, 2020
CLSA highlights that it was a muted month for pharma companies as November sales disappoint for the Domestic Market. CLSA says it was a strong month for IPCA Labs; gains from integration of acquired brands for Dr Reddy. Falling active cases meant sales of Covid treatment drugs moderated for Glenmark / Cipla (+16%/-24% MoM). Glenmark saw the highest growth in its coverage in November, but excluding these products, its portfolio fell 1% YoY. Cipla’s core growth was a smaller 5.9% YoY.
Tue, Dec 15, 2020
Among the top 30 companies Mylan clocked the highest growth of 144% for November followed by Glenmark Pharma(+11%), IPCA Labs (+10%) and Ajanta Pharma(+10%) clocking double digit growth while Novartis, Micro, Indoco Remedies, FDC & Mankind Pharma were impacted the most. With 144% growth for the month (sales of Rs 920 m), Mylan has been the standout performer for the month primarily aided by Rs 540 mn sales contribution from its COVID treatment drug, Desrem. Notably, Desrem was the second largest selling brand in IPM for Nov20. Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life were among some local listed players that clocked a single digit growth.
The Nifty opened with a gain of 60 points on December 14, 2020, in line with strong cues from global markets. Thereafter, the Nifty went in negative zone due to profit booking at higher levels. Barring Nifty Auto and Reality indices, all other indices closed in the positive zone rising by 1-2%. In the afternoon, the Nifty managed to turn positive aided by buying at lower levels. Stocks like ONGC, LT, CIPLA, COALINDIA and IOC were top gainers that rose by 3-4%, while stocks like EICHERMOT, HEROMOTOCO, M&M, HDFCLIFE and TECHM were top losers that fell by 2-3%. The Nifty closed at around 13568 levels with a gain of 0.21%.
Mon, Dec 14, 2020
Cipla is licensed to sell volume-limited quantity after Mar 2022 and without volume-restriction after Jan 31, 2026 subject to product approval from the US FDA. While the details pertaining to launch date and market share are not disclosed, the opportunity can add an NPV of Rs4 0/share to target price in a base case scenario (assuming 5-10% market share, 30-50% price erosion between FY23-26). HDFC Securities increased their target price to Rs 940 to factor gRevlimid launch in FY23 and maintained BUY rating. Key catalysts are ramp-up in Albuterol, progress on IV Tramadol, limited competition launches in the US.
Tue, Nov 24, 2020
AstraZeneca vaccine will be able to vaccinate only 50% of the population by the end 2022, even if there are no supply/ funding constraints, according to Jefferies. A 70% efficacy with AstraZeneca would further delay the time to bring the Pandemic under control in India. High unmet demand leaves potential for other vaccine plays in India. Remdesivir could also see extended sales for Cipla and Cadila Healthcare.
Wed, Nov 11, 2020
Nifty Pharma now trades at a 12% premium to Nifty, this compares to a long-term average premium of 38%. Macquarie stays positive on India pharma companies. Dr Reddy's, Cipla and Divi's Labs are their top stock picks in large-cap pharma space while Syngene, Solara and Jubilant life are preferred mid-cap picks.
Fri, Nov 06, 2020
CGSCIMB says they believe the domestic business’s strong recovery in growth should ensure healthy cash flows and better RocE. They initiate coverage on the Pharma sector with Overweight rating; add rating on Dr Reddy’s Labs, Cadila Healthcare, Alkem Labs, Cipla, IPCA Labs, Natco Pharma, Ajanta Pharma, Indoco Remedies and Hold rating on Alembic Pharma, Torrent Pharma.
Thu, Nov 05, 2020
Benchmark Nifty has rebounded sharply after hitting the levels of 7510 in the month of March 2020. The index is in the third leg of a major corrective pattern. It is correcting after hitting the crucial and psychological mark of 12000. Until the market is above the level of 10800 (previous significant bottom), Nifty would keep rallying. Below 10800 levels Nifty would lose its momentum and may even fall to 10300 levels. On the decisive crossing of 12400 levels would lift the Nifty to 13300 levels.
Fri, Oct 09, 2020
CLSA believes that fundamentals for the pharma sector in 2020 are much healthier than even in 2015.
Mon, Oct 05, 2020
In a significant move today that has wide-ranging ramifications for the segment, ex-Cipla India Business CEO Nikhil Chopra has joined JB Chemicals as a Whole Time Director and CEO today for a tenure of 5 years.
Thu, Aug 13, 2020
Top Stocks to Buy Today: Zee Business Fast Money team has come out with 20 top shares that can help traders mint money at a faster rate.
Wed, Aug 12, 2020
Kedar Upadhye, Global Chief Financial Officer, Cipla Limited, talks about Albuterol, the US business, product pipelines, margins and Goa facility among others during a candid chat with Swati Khandelwal, Zee Business.
Mon, Aug 10, 2020
Stock markets today ended the day in the green. While the BSE Sensex was trading at 38,182 at the close, up by over 0.3 per cent or 141 points, the broader market NSE Nifty 50 was trading 11,274.70, up by over 0.5 per cent 60 points around this time from the previous close on Friday
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
